Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions

Inclusion Criteria: To participate in the study, all of the following inclusion criteria must be met:

1. Patients (m/f/d) at the age of ≥18
2. Written declaration of consent
3. Asthma diagnosis according to German Asthma Guideline NVL, 4th edition
4. Suitability for a therapy with MF/IND/GLY in combination with the sensor system oranother ICS+LABA+LAMA FDC according to SPC
5. At least 6 months of inhaled therapy with ICS+LABA (high dose) or ICS+LABA+LAMA (medium or high dose) before switching or escalating asthma medication at baseline
6. Change or escalation of the asthma medication to MF/IND/GLY in combination with thesensor system or another ICS+LABA+LAMA FDC according to the therapy decision of thetreating physician
7. Availability of at least one ACT value of the last 6 months before consent
8. Cohort treated with MF/IND/GLY in combination with the sensor system

• Owning an Android or iOS smartphone or tablet on which the app can be installed (via WiFi or mobile data network) and run (requires about 75 megabytes of storagespace) and which is capable of establishing a Bluetooth connection to the sensorThe patient must agree to activate the app, the Bluetooth connection and themobile data connection regularly (at least once a month).
• Availability of an e-mail address

Exclusion Criteria: To participate in the study, none of the following exclusion criteria must apply:

1. Use of a digital inhaler-coupled inhalation tracking system to support adherence inthe last 3 months prior to study entry
2. Simultaneous participation in an interventional study or in another Novartis-sponsorednoninterventional study
3. Asthma therapy with a biological agent, if not stable at the same dosage for at least 3 months